Showing 1541-1550 of 1692 results for "".
- Intranasal Foralumab Provides Neuroimaging and Clinical Improvements in Secondary Progressive Multiple Sclerosishttps://practicalneurology.com/news/intranasal-foralumab-provides-neuroimaging-and-clinical-improvements-in-secondary-progressive-multiple-sclerosis/2469929/In the expanded access program, after 3 months of intranasal foralumab (Tiziana Life Sciences, New York, NY) treatment of secondary progressive multiple sclerosis (SPMS), a second participant showed clinical improvement on Positron Emission Tomography (PET) imaging analysis, neurologic exami
- Subcutaneous Formulation of Carbidopa/Levodopa for Parkinson Disease Submitted to FDA for Approvalhttps://practicalneurology.com/news/subcutaneous-formulation-of-carbidopalevodopa-for-parkinson-disease-submitted-to-fda-for-approval/2469915/A new drug application was submitted to the FDA for a new formulation of of foscarbidopa/foslevodopa (CD/LD) (ABBV-951; Abbvie, Chicago, IL) delivered subcutaneously for treatment of Parkinson disease (PD). In a clinical trial (
- FDA Approves Transdermal Formulation of Donepezil for Alzheimer Diseasehttps://practicalneurology.com/news/fda-approves-transdermal-formulation-of-donepezil-for-alzheimer-disease/2469848/The Food and Drug Administration (FDA) has approved a transdermal formulation of donepezil (Adlarity; Corium, Boston, MA) for treatment of mild, moderate, or severe dementia from Alzheimer disease (AD). The transdermal patch delivers 5 or 10 mg/day for 7 days. This formulation is
- Once-Nightly Oxybate Formulation Effective and Preferred by People With Narcolepsyhttps://practicalneurology.com/news/once-nightly-oxybate-formulation-effective-and-preferred-by-people-with-narcolepsy/2469726/Post hoc analysis of data from the pivotal phase 3 REST-ON trial showed a once-nightly formulation of sodium oxybate (ON-SXB)(FT218; Avadel Pharmaceuticals, Dublin, Ireland), reduced weekly cataplexy attacks and improved sleep latency compared with placebo. Among participants who receiv
- FDA Approves New Occlusion System for Treatment of Patent Foramen Ovale to Prevent Recurrent Strokehttps://practicalneurology.com/news/fda-approves-new-occlusion-system-for-treatment-of-patent-foramen-ovale-to-prevent-recurrent-stroke/2469706/The Food and Drug Administration (FDA) has approved a new occluder (Amplatzer Talisman; Abbot, Chicago, IL) for treatment of patent foramen ovale (PFO) in individuals at risk of a recurrent stroke. The FDA also cleared the delivery sheath, used to del
- Once-A-Night Formulation of Sodium Oxybate Improves Excessive Daytime Sleepiness and Reduces Catplexy in Narcolepsyhttps://practicalneurology.com/news/once-a-night-formulation-of-sodium-oxybate-improves-excessive-daytime-sleepiness-and-reduces-catplexy-in-narcolepsy/2469669/Data from a pivotal phase 3 clinical study published in Sleep reveal that an investigational formulation of sodium oxybate (FT218; Avadel Pharmaceuticals, Dublin, Ireland), taken only once
- FDA Accepts New Drug Application for New Dihydroergotamine Formulation for Acute Treatment of Migrainehttps://practicalneurology.com/news/fda-accepts-new-drug-application-for-new-dihydroergotamine-formulation-for-acute-treatment-of-migraine/2469479/The Food and Drug Administration (FDA) has accepted the new drug application (NDA) for a new formulation of dihydroergotamine (DHE) (inp104; Trudhesa; Impel Neuropharma, Seattle, WA) for the acute treatment of migraine with or without aura. If approved, this formulation of DHE will be the first t
- Long-Term Freedom from Seizure With Perampanel Treatmenthttps://practicalneurology.com/news/long-term-freedom-from-seizure-with-perampanel-treatment/2469455/In a post-hoc analysis, of the phase 3 FREEDOM study (NCT03201900), 62.5% of individuals treated with 4 to 8 mg/day of perampanel (Fycompa, Eisai Inc, Woodcliff Lake, NJ) achieved seizure freedom for 1 year. Participants in the study w
- Laser Thermal Ablation Therapy Brings Seizure Freedom to 54% of Children Treatedhttps://practicalneurology.com/news/laser-thermal-ablation-therapy-brings-seizure-freedom-to-54-of-children-treated/2469450/A new study being presented virtually at American Epilepsy Society AES2020 showed MRI-guided laser interstitial thermal therapy (MR-LITT) in children with medically refractory epilepsy, achieved seizure freedom for 54% 1 year after the procedure. Children treated (n=182) were age 14 months of age
- Minimally Invasive Laser Ablation Epilepsy Surgery Provides 64% Treated With Seizure Freedomhttps://practicalneurology.com/news/minimally-invasive-laser-ablation-epilepsy-surgery-provides-64-treated-with-seizure-freedom/2469423/Results published in Epilepsy Research, showed minimally invasive laser ablation epilepsy surgery (NeuroBlate System; Monteris Medical, Plymouth, MN) resulted in seizure freedom for 64% of those treated (n=42) measured 12 months after the procedure. Individuals who had the procedure had medically